Cardiora Pty Ltd

‚Äč

Level 9, 31 Queen St, Melbourne VIC 3000

ABN: 33 606 313 642

+613 9657 0700

Cardiora is a clinical stage pharmaceutical company focused on the development of CRD-102, a new oral medicine for the treatment of end stage heart failure.

Cardiora

Heart failure affects more than 6 million people in the U.S alone, and results in more than one million hospital admissions every year.

 

In spite of significant medical advances, heart failure remains an area of ongoing clinical need.

 

Founded in 2015, Cardiora is developing CRD-102, a proprietary formulation of extended release oral milrinone to treat patients with heart failure.